Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...

Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects ...

Evotec's other major shareholders are Novo Nordisk (NOVOb.CO), opens new tab parent Novo Holdings and Mubadala Investment. "The combination of Halozyme and Evotec would diversify and extend ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins ...

Novo Holdings, the parent company of Novo Nordisk (NYSE:NVO), and Mubadala Investment are among Evotec’s other significant shareholders. "The combination of Halozyme and Evotec would diversify ...

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases ...

MiscellaneousEvotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk 11.12.2024 / 07:29 CET/CESTThe issuer is solely responsible for the content of this ...